209 related articles for article (PubMed ID: 21404058)
1. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis.
Rao B; Gao Y; Huang J; Gao X; Fu X; Huang M; Yao J; Wang J; Li W; Zhang J; Liu H; Wang L; Wang J
Int J Colorectal Dis; 2011 May; 26(5):593-601. PubMed ID: 21404058
[TBL] [Abstract][Full Text] [Related]
2. Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.
Ines C; Donia O; Rahma B; Ben Ammar A; Sameh A; Khalfallah T; Abdelmajid BH; Sabeh M; Saadia B
Tumour Biol; 2014 Jul; 35(7):7163-75. PubMed ID: 24763823
[TBL] [Abstract][Full Text] [Related]
3. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians.
Malhotra P; Anwar M; Nanda N; Kochhar R; Wig JD; Vaiphei K; Mahmood S
Tumour Biol; 2013 Jun; 34(3):1901-11. PubMed ID: 23526092
[TBL] [Abstract][Full Text] [Related]
4. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
5. Critical Role of p53 and K-ras in the Diagnosis of Early Colorectal Cancer: a One-year, Single-center Analysis.
Lu HY; Lin RT; Zhou GX; Yu TM; Liu ZJ
Int J Med Sci; 2017; 14(11):1154-1162. PubMed ID: 29104470
[No Abstract] [Full Text] [Related]
6. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
Russo A; Bazan V; Agnese V; Rodolico V; Gebbia N
Ann Oncol; 2005 May; 16 Suppl 4():iv44-49. PubMed ID: 15923428
[TBL] [Abstract][Full Text] [Related]
8. Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer.
Schimanski CC; Moehler M; Gockel I; Zimmermann T; Lang H; Galle PR; Berger MR
J Cancer Res Clin Oncol; 2011 Jul; 137(7):1139-45. PubMed ID: 21468700
[TBL] [Abstract][Full Text] [Related]
9. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
Tentler JJ; Nallapareddy S; Tan AC; Spreafico A; Pitts TM; Morelli MP; Selby HM; Kachaeva MI; Flanigan SA; Kulikowski GN; Leong S; Arcaroli JJ; Messersmith WA; Eckhardt SG
Mol Cancer Ther; 2010 Dec; 9(12):3351-62. PubMed ID: 20923857
[TBL] [Abstract][Full Text] [Related]
10. p73 Isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis.
Díaz R; Peña C; Silva J; Lorenzo Y; García V; García JM; Sánchez A; Espinosa P; Yuste R; Bonilla F; Domínguez G
Int J Cancer; 2008 Sep; 123(5):1060-7. PubMed ID: 18546269
[TBL] [Abstract][Full Text] [Related]
11. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
13. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
Ince WL; Jubb AM; Holden SN; Holmgren EB; Tobin P; Sridhar M; Hurwitz HI; Kabbinavar F; Novotny WF; Hillan KJ; Koeppen H
J Natl Cancer Inst; 2005 Jul; 97(13):981-9. PubMed ID: 15998951
[TBL] [Abstract][Full Text] [Related]
14. Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review.
Rui YY; Zhang D; Zhou ZG; Wang C; Yang L; Yu YY; Chen HN
PLoS One; 2013; 8(10):e77901. PubMed ID: 24205021
[TBL] [Abstract][Full Text] [Related]
15. A gene marker panel covering the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene mutations in 80% of early (UICC I) colon cancer stages in humans.
Scholtka B; Schneider M; Melcher R; Katzenberger T; Friedrich D; Berghof-Jäger K; Scheppach W; Steinberg P
Cancer Epidemiol; 2009 Aug; 33(2):123-9. PubMed ID: 19679059
[TBL] [Abstract][Full Text] [Related]
16. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
[TBL] [Abstract][Full Text] [Related]
17. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.
Bazan V; Agnese V; Corsale S; Calò V; Valerio MR; Latteri MA; Vieni S; Grassi N; Cicero G; Dardanoni G; Tomasino RM; Colucci G; Gebbia N; Russo A;
Ann Oncol; 2005 May; 16 Suppl 4():iv50-55. PubMed ID: 15923430
[TBL] [Abstract][Full Text] [Related]
18. P21WAF1/CIP1 expression in colorectal carcinomas is related to Kras mutations and prognosis.
Mitomi H; Ohkura Y; Fukui N; Kanazawa H; Kishimoto I; Nakamura T; Yokoyama K; Sada M; Kobayashi K; Tanabe S; Saigenji K
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):883-9. PubMed ID: 17873613
[TBL] [Abstract][Full Text] [Related]
19. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
20. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome.
Flanagan L; Schmid J; Ebert M; Soucek P; Kunicka T; Liska V; Bruha J; Neary P; Dezeeuw N; Tommasino M; Jenab M; Prehn JH; Hughes DJ
Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1381-90. PubMed ID: 24599709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]